Unlike ABBV’s patent estate in the US, which has enabled settlements that delay US Humira FoBs until 2023, ABBV’s Humira patents in European countries begin expiring in the next few months.
The 9/30/23 launch date in the US market is 2 months later than MYL’s launch date (#msg-142251299), 3 months later than Samsung’s launch date (#msg-139804103), and 8 months later than AMGN’s launch date (#msg-134976468).
I.e. AMGN, the first company to settle with ABBV, got a 6-month head start in the US market relative to all other Humira biosimilars; the settlements from the second to the fourth (and presumably additional ones to come) have US launch spaced 1 month apart, so there’s a tangible disincentive to the settling companies for waiting.
News 
Market Data 
Discover 
